Amyotrophic Lateral Sclerosis
Amylyx Reveals Interim Rare Disease Data for Withdrawn ALS Therapy
Amylyx, Rare disease data, ALS drug withdrawal, Interim results, Rare neurological disorder
FDA Approves BrainStorm’s Phase IIIb Trial Design for NurOwn in Early-Stage ALS
BrainStorm Cell Therapeutics, NurOwn, Phase IIIb trial, Special Protocol Assessment (SPA), FDA agreement, Early-stage ALS, Amyotrophic Lateral Sclerosis (ALS)
Experts Commend Amylyx for Withdrawing ALS Drug Relyvrio Following Trial Failure
Amylyx, Relyvrio, ALS drug, Trial failure, Market withdrawal, Promise kept
Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal
Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance
“Regulating Hope Amidst Uncertainties: Novel ALS Treatments Face Complex Challenges”
ALS Treatments, Regulatory Uncertainty, Clinical Trials, Relyvrio, Masitinib, Antisense Therapy, Risk-Benefit Analysis, FDA Approval, Patient Advocacy
Improving Amylyx’s ALS Drug Relyvrio: Taste Masking and Withdrawal
Amylyx, ALS, Relyvrio, Taste Masking, Withdrawal, Patent Life
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s